FINCAD Launches Pioneering Python Toolkit for Valuation and Risk Analytics
FINCAD, the leading provider of enterprise solutions for derivative and fixed income portfolios, today announced innovative enhancements to FINCAD F3, an advanced valuation and risk analytics solution. A comprehensive Python toolkit has been added to F3, enabling traders, quants, portfolio managers and risk managers to rapidly generate custom analytics, applications and reports to drive better investment and risk decisions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181011005479/en/
FINCAD F3 Python Trade Script for a TARN (Photo: Business Wire)
Due to its versatility and ease of use, Python has achieved widespread adoption in finance, and has become the multi-purpose tool of choice for quantitative analysts and other financial technologists. However, while it is easy to start projects with Python, deploying them to production can be challenging, and teams often struggle with infrastructure issues such as data management, calculation scaling, version control, admin and security.
The F3 Python toolkit helps clients address this challenge by combining Python’s sophisticated capabilities, FINCAD’s industry-standard analytics library and the enterprise-class technology of F3 Platform, which automatically handles the infrastructure issues. The result is that portfolio managers, traders, and quants can maximize their productivity and focus on creating real business value without the heavy burden of enterprise infrastructure and software concerns. Common use cases cover a wide range, including strategy back-testing, structured product scripting, portfolio optimization, tailored hedging strategies, LDI portfolio construction, cash flow matching, custom pre-trade analytics, risk reports and real-time dashboards.
“Python enables clients to be incredibly productive and it has a rich ecosystem that is ideally suited to portfolio and risk analysis,” said James Church, VP of R&D at FINCAD. “The F3 Python toolkit goes far beyond a simple Python API, and brings together best-of-breed pricing and risk analytics, enterprise scalability, data management and UI tools so that teams can collaborate on ideas, then take them quickly and easily into production.”
The FINCAD F3 Python toolkit includes an F3 Python SDK, F3 Python MicroServices and F3 Python Trade Scripting which enable users to:
- Rapidly deliver custom analytics: Leverage Numpy, Scipy, pandas, Plotly and other standard Python libraries with the most up-to-date Python features to create custom analytics, such as portfolio optimizers, which can be integrated into other applications.
- Easily create custom applications and reports: Native integration with Jupyter Notebooks and Jupyter Lab, PyCharm, Visual Studio and Visual Studio Code, enable faster report and application development with familiar tools, without needing to learn a new development environment. Also included are tools for building rich, interactive UIs without being a developer; and it comes with a complete set of widgets for reporting, selecting books, trades and models, and for handling many types of financial inputs and outputs.
- Quickly model and script complex payoffs: Use Python’s concise, highly expressive syntax with F3 analytics and data. Complex modeling and scripting can be abstracted away or dealt with using data-driven approaches.
“With enterprise portfolio and risk systems, one size doesn’t fit all,” noted Bob Park, FINCAD President and CEO. “Every investment firm is unique, and their software should be flexible and able to adapt to their specific needs, workflows and requirements. With FINCAD F3, firms don’t have to settle for software that is ‘good enough’, nor do they have to make compromises. They get the unparalleled combination of powerful out-of-the-box functionality and the flexibility for unlimited customization using versatile tools such as Python.”
FINCAD is the leading provider of valuation and risk solutions for derivative and fixed income portfolios. An industry standard since 1990, our advanced analytics, flexible architecture and patented technology enable better investment and risk management decisions. We are committed to helping our clients solve their toughest challenges, without compromise. Clients include leading global asset managers, hedge funds, insurance companies, pension funds, banks and auditors. For more information, visit www.fincad.com.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00 | Pressemelding
Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp
Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00 | Pressemelding
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te
Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00 | Pressemelding
Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented
Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00 | Pressemelding
Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is
Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00 | Pressemelding
Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of
Lenovo Data Center Group Delivers Broad Edge Computing Portfolio, Expands Investments in IoT22.2.2019 13:13:00 | Pressemelding
Next week at MWC Barcelona, Lenovo Data Center Group (DCG) will showcase continued investments in its solutions supporting IoT and edge computing as part of its IoT growth plan over the next few years. Building on the momentum of its fifth consecutive quarter of profit growth, Lenovo DCG is building a portfolio that takes infrastructure to where the data is, whether that be in the traditional data center, in the cloud or increasingly, at the edge. Today, around 10 percent of enterprise-generated data is created and processed outside a traditional centralized data center or cloud. By 2022, Gartner predicts this figure will reach 75 percent. This migration is driving increased concerns around data privacy, security and regulations coupled with challenges of latency, bandwidth and downtime. Lenovo is addressing these challenges by creating a broad portfolio of edge computing offerings that address the different ways that customers want to deploy edge computing solutions for IoT use cases.